新型液体栓塞剂治疗脑动静脉畸形的7年单中心安全性经验
6个月血管造影治愈率为53.3%,非黏附性栓塞剂高于Glue(65.3% vs 17.6%,P < .001)。出血是并发症和死亡的主要贡献因素,深静脉引流是出血和死亡的独立预测因素。
要点
- PHIL和Squid的并发症率和血管造影治愈率与Onyx相当。
- Glue与较低的血管造影闭塞率独立相关(OR=9.1)。
- 深静脉引流是出血和死亡的独立预测因素。
核心结论
- PHIL和Squid的并发症率和血管造影治愈率与Onyx相当,但脑动静脉畸形治愈性栓塞的血管造影闭塞率仅为中等水平。
主要发现
- 6个月血管造影治愈率为53.3%,非黏附性栓塞剂高于Glue(65.3% vs 17.6%,P < .001)。
- 技术操作并发症率10.2%(致残率2.2%),出血并发症率13.1%(致残率3.7%,死亡率2.2%),缺血并发症率9.2%(致残率2.2%,死亡率0%)。
- 轻微并发症率3.7%,严重并发症率4.4%,死亡率2.2%。
- 调整分析中, eloquent位置(OR=4.4,P=.007)和Glue(OR=9.1,95%CI 2.9-28.9,P < .001)是较低血管造影闭塞率的预测因素,大小呈负相关(OR=0.67,P=.019)。
- 深静脉引流是出血和死亡的独立预测因素。
临床怎么用
- 选择液体栓塞剂时,PHIL和Squid可作为Onyx的替代选择,其安全性和治愈率相当。
- 对于深静脉引流的脑动静脉畸形患者,应警惕出血和死亡风险。
局限性
- 单中心回顾性设计,样本量有限,需更大规模多中心研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Embolization is part of multidisciplinary brain arteriovenous malformations (AVMs) treatment, yet safety data for novel liquid embolization agents (LEAs) such as Squid and PHIL remain limited. This study reports complications and outcomes from curative embolization using Onyx, Squid, PHIL, and Glue. METHODS: Adult patients with brain AVMs treated with LEAs from July 2015 to December 2022 were reviewed for intraprocedural technical issues, postoperative hemorrhagic, and ischemic complications. Minor (modified Rankin Scale ≤2) and major complication rate (morbidity/modified Rankin Scale >2), mortality, and 6-month angiographic cure rate were evaluated. RESULTS: In total, 135 patients (62.2% male, mean age 41.7 ± 15.1 years) with 206 embolizations (34% Onyx, 18.9% Squid, 17.5% PHIL, 28.2% Glue) were included. Overall, 87.4% procedures were in ruptured AVMs and 84% treated by the transarterial technique (84%). The 6-month angiographic cure rate was 53.3%, higher when nonadhesive LEAs were used than Glue (65.3% vs 17.6%, P < .001). In adjusted analysis, only eloquent location (odds ratio [OR] = 4.4; P = .007) and Glue (OR = 9.1; 95% CI 2.9-28.9, P < .001) were predictors of lower angiographic occlusion rate, whereas size had an inverse correlation (OR = 0.67; P = .019). Technical procedural complications, hemorrhagic, and ischemic rates were 10.2% (2.2% morbidity), 13.1% (3.7% morbidity and 2.2% mortality), and 9.2% (2.2% morbidity, 0% mortality), respectively, regardless of the preferred LEA. Minor, major complications, and mortality rates were 3.7%, 4.4%, and 2.2%, respectively. Hemorrhage was the major contributor to morbidity and mortality, whereas deep venous drainage was an independent predictor of hemorrhage and mortality. CONCLUSION: PHIL and Squid demonstrated complication and angiographic cure rates comparable with Onyx. However, curative embolization of brain AVMs resulted in only moderate angiographic occlusion. Larger multicenter studies with standardized operator protocols, cost-effectiveness assessments, and extended follow-up are warranted to validate these findings.
引用
- de Oliveira Souza NV, Cortese J, Soize S, et al. Endovascular Treatment of Brain Arteriovenous Malformations After New Liquid Embolic Agents: A Single-Center 7-Year Experience With Safety Outcomes. Neurosurgery. 2025. PMID: 40874751. doi:10.1227/neu.0000000000003691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。